NEW YORK (GenomeWeb News) – Vermillion has tapped Thomas McLain to be president and CEO, replacing interim CEO Bruce Huebner, who will retain his position as a company director.

McLain formerly was CEO and CFO of Claro Scientific, an early-stage diagnostic company, and he held senior management positions at Nabi Biopharmaceuticals and was a member of the board of the Biotechnology Industry Organization.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.